Multiple System Atrophy clinical trials at University of California Health
4 in progress, 1 open to eligible people
Trial of Parkinson's And Zoledronic Acid
open to eligible people ages 60 years and up
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.
at UC Davis UC Irvine UCLA UCSF
GDNF Gene Therapy for Multiple System Atrophy
Sorry, not yet accepting patients
The objective of this randomized, double-blinded, placebo-controlled Phase 1 investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a possible or probable diagnosis of Multiple System Atrophy.
at UC Irvine
North American Prodromal Synucleinopathy Consortium
Sorry, accepting new patients by invitation only
This study will enroll participants with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD), for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
at UCLA
Study of BHV-3241 in Subjects With Multiple System Atrophy
Sorry, in progress, not accepting new patients
The purpose of this study is to compare the efficacy of BHV-3241 versus placebo in subjects with Multiple System Atrophy
at UCLA UCSD UCSF
Our lead scientists for Multiple System Atrophy research studies include Nicolas Phielipp, MD Caroline Tanner, MD.
Last updated: